Carlisle Companies Inc (CSL)

102.08
1.38 1.33
NYSE : Consumer Goods
Prev Close 103.46
Open 103.10
Day Low/High 102.06 / 103.62
52 Wk Low/High 75.17 / 109.13
Volume 152.34K
Avg Volume 308.60K
Exchange NYSE
Shares Outstanding 64.62M
Market Cap 6.59B
EPS 4.90
P/E Ratio 18.21
Div & Yield 1.40 (1.40%)

Latest News

Carlisle Authorizes Repurchase Of An Additional 4.1 Million Shares

Carlisle Authorizes Repurchase Of An Additional 4.1 Million Shares

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has authorized Carlisle to repurchase an additional 4.

Carlisle Companies Elects Jonathan Collins To Board Of Directors

Carlisle Companies Elects Jonathan Collins To Board Of Directors

Carlisle Companies Incorporated (NYSE:CSL) announced today that Jonathan Collins, Vice President and Head of eCommerce for Mylan N.

Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older

Seqirus receives FDA approval for AFLURIA® QUADRIVALENT (Influenza Vaccine) for people 18 years of age and older

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Seqirus To Highlight New Data In Seasonal Influenza Prevention At Options IX For The Control Of Influenza Conference

Seqirus To Highlight New Data In Seasonal Influenza Prevention At Options IX For The Control Of Influenza Conference

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Seqirus Presents Integrated Analyses For Trivalent Adjuvanted Seasonal Influenza Vaccine For Young Children

Seqirus Presents Integrated Analyses For Trivalent Adjuvanted Seasonal Influenza Vaccine For Young Children

NOTE TO EDITORS:On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Seqirus Now Shipping Its Complete Portfolio Of Seasonal Influenza Vaccines To US Market For The 2016-2017 Season

Seqirus Now Shipping Its Complete Portfolio Of Seasonal Influenza Vaccines To US Market For The 2016-2017 Season

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Seqirus Announces Shipment Of FLUAD™ (Influenza Vaccine, Adjuvanted) In The US For 2016-2017 Flu Season

Seqirus Announces Shipment Of FLUAD™ (Influenza Vaccine, Adjuvanted) In The US For 2016-2017 Flu Season

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

IIROC Trading Resumption - CSL; SNS

IIROC Trading Resumption - CSL; SNS

IIROC Trading Halt - QXP; CSL; SNS

IIROC Trading Halt - QXP; CSL; SNS

Carlisle Companies Announces 17% Increase In Dividend And The 40th Consecutive Year Of Dividend Increases

Carlisle Companies Announces 17% Increase In Dividend And The 40th Consecutive Year Of Dividend Increases

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a 17% increase in the Company's regular quarterly dividend, to $0.

CSL Behring Presents Pivotal Efficacy Data For AFSTYLA® In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress

CSL Behring Presents Pivotal Efficacy Data For AFSTYLA® In Adolescents And Children With Hemophilia A At The World Federation Of Hemophilia 2016 World Congress

-AFSTYLA prophylaxis and on-demand treatment demonstrated long-lasting hemostatic efficacy in pediatric patients with severe hemophilia A in phase III data presented

CSL Behring Presents Phase III Data For IDELVION® For Hemophilia B At The World Federation Of Hemophilia 2016 World Congress

CSL Behring Presents Phase III Data For IDELVION® For Hemophilia B At The World Federation Of Hemophilia 2016 World Congress

New analyses from global PROLONG-9FP clinical development program show:

Carlisle Reports Record Earnings Per Share From Continuing Operations Of $1.75, A 22% Increase Over The Prior Year, And Record EBIT Margin Of 17.9% In The Second Quarter 2016

Carlisle Reports Record Earnings Per Share From Continuing Operations Of $1.75, A 22% Increase Over The Prior Year, And Record EBIT Margin Of 17.9% In The Second Quarter 2016

Carlisle Companies Incorporated (NYSE:CSL) reported net sales from continuing operations of $996.

CSL Plasma Raises Over $118,000 For The Immune Deficiency Foundation

CSL Plasma Raises Over $118,000 For The Immune Deficiency Foundation

New Giving Record Set

CSL Behring To Present New Data For IDELVION® And AFSTYLA® At The World Federation Of Hemophilia 2016 World Congress

CSL Behring To Present New Data For IDELVION® And AFSTYLA® At The World Federation Of Hemophilia 2016 World Congress

Abstracts include pivotal efficacy and safety data for IDELVION for hemophilia B and AFSTYLA for hemophilia A; AFSTYLA and IDELVION demonstrate CSL Behring's promise to develop and deliver innovative treatments that help patients with serious medical conditions live full lives

U.S. FDA Approves CSL Behring's Berinert® As The First And Only Pediatric Treatment For Hereditary Angioedema (HAE)

U.S. FDA Approves CSL Behring's Berinert® As The First And Only Pediatric Treatment For Hereditary Angioedema (HAE)

Berinert is the only C1 Esterase Inhibitor concentrate approved for on-demand treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) attacks in adult and pediatric patients.

Seqirus Is First-to-market With Shipment Of Seasonal Influenza Vaccines To The US For The 2016-2017 Season

Seqirus Is First-to-market With Shipment Of Seasonal Influenza Vaccines To The US For The 2016-2017 Season

NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.

Carlisle Companies To Announce 2nd Quarter Results On July 26, 2016

Carlisle Companies To Announce 2nd Quarter Results On July 26, 2016

Carlisle Companies Incorporated (NYSE:CSL) will release second quarter 2016 results on Tuesday, July 26, 2016 before the market opens.

CSL Behring Announces Immunoglobulin Research Grant Winners

CSL Behring Announces Immunoglobulin Research Grant Winners

2016 Interlaken Leadership Awards to Advance Neurological Disorders Research

AFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy For Hemophilia A - Now Available In The U.S.

AFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy For Hemophilia A - Now Available In The U.S.

AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available

Short Interest In Carlisle Companies Moves 38.3% Higher

Short Interest In Carlisle Companies Moves 38.3% Higher

The most recent short interest data has been released for the 05/31/2016 settlement date, which shows a 462,715 share increase in total short interest for Carlisle Companies Inc. , to 1,670,050, an increase of 38.33% since 05/13/2016.

Carlisle Acquires Micro-Coax

Carlisle Acquires Micro-Coax

Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of Micro-Coax, Inc.

Today's Weak On High Volume Stock: Carlisle Companies (CSL)

Today's Weak On High Volume Stock: Carlisle Companies (CSL)

Trade-Ideas LLC identified Carlisle Companies (CSL) as a weak on high relative volume candidate

Carlisle Companies To Present At KeyBanc's Conference In Boston June 1

Carlisle Companies To Present At KeyBanc's Conference In Boston June 1

D. Christian "Chris" Koch, President and Chief Executive Officer of Carlisle Companies Incorporated (NYSE:CSL), will be conducting a General Session at KeyBanc's Conference at the InterContinental Hotel in Boston, MA at...

U.S. FDA Approves CSL Behring's AFSTYLA® -- The First And Only Recombinant Factor VIII Single Chain Therapy For Hemophilia A

U.S. FDA Approves CSL Behring's AFSTYLA® -- The First And Only Recombinant Factor VIII Single Chain Therapy For Hemophilia A

- AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available

Carlisle Appoints Kevin P. Zdimal Vice President Of Business Development; Carlisle Appoints Titus B. Ball Vice President And Chief Accounting Officer

Carlisle Appoints Kevin P. Zdimal Vice President Of Business Development; Carlisle Appoints Titus B. Ball Vice President And Chief Accounting Officer

Carlisle Companies Incorporated (NYSE:CSL) announced today the appointment of Kevin P.